Peregrine Pharmaceuticals Inc. (PPHM) Position Reduced by Bank of New York Mellon Corp
Bank of New York Mellon Corp decreased its stake in Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) by 1.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195,528 shares of the biopharmaceutical company’s stock after selling 2,768 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.43% of Peregrine Pharmaceuticals worth $119,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Eqis Capital Management Inc. boosted its stake in Peregrine Pharmaceuticals by 1.0% in the 2nd quarter. Eqis Capital Management Inc. now owns 1,052,770 shares of the biopharmaceutical company’s stock valued at $642,000 after buying an additional 10,398 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Peregrine Pharmaceuticals by 495.7% in the 1st quarter. Wells Fargo & Company MN now owns 228,628 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 190,250 shares in the last quarter. KCG Holdings Inc. boosted its stake in Peregrine Pharmaceuticals by 941.5% in the first quarter. KCG Holdings Inc. now owns 238,906 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 215,967 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Peregrine Pharmaceuticals in the first quarter worth $210,000. Finally, Geode Capital Management LLC boosted its stake in Peregrine Pharmaceuticals by 31.6% in the first quarter. Geode Capital Management LLC now owns 1,437,491 shares of the biopharmaceutical company’s stock worth $940,000 after purchasing an additional 344,811 shares in the last quarter.
A number of equities analysts have commented on the company. BidaskClub raised Peregrine Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research lowered Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 21st. Noble Financial reissued a “buy” rating on shares of Peregrine Pharmaceuticals in a research note on Monday, July 31st. Finally, ValuEngine lowered Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st.
In other Peregrine Pharmaceuticals news, Director Mark R. Bamforth acquired 50,000 shares of Peregrine Pharmaceuticals stock in a transaction on Friday, October 27th. The shares were bought at an average price of $4.50 per share, with a total value of $225,000.00. Following the completion of the purchase, the director now owns 200 shares in the company, valued at $900. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.85% of the stock is currently owned by insiders.
Peregrine Pharmaceuticals Inc. (PPHM) opened at $4.40 on Tuesday. Peregrine Pharmaceuticals Inc. has a one year low of $1.97 and a one year high of $5.78.
Peregrine Pharmaceuticals (NASDAQ:PPHM) last posted its quarterly earnings data on Monday, September 11th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The company had revenue of $27.08 million for the quarter, compared to analyst estimates of $15.22 million. Peregrine Pharmaceuticals had a negative return on equity of 38.19% and a negative net margin of 23.15%. research analysts anticipate that Peregrine Pharmaceuticals Inc. will post -0.43 EPS for the current fiscal year.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
Receive News & Stock Ratings for Peregrine Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.